Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease

Annals of Neurology

Volumn 42, Issue 2, 1997, Pages 215-221

  Augood, S J ^a   Faull, R L M ^b   Emson, P C ^a  

^a BABRAHAM INSTITUTE   (United Kingdom)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; MESSENGER RNA;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; IN SITU HYBRIDIZATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; CELL SURVIVAL; GENETIC TRANSCRIPTION; GENETICS; HETEROZYGOTE; INTERNEURON; METABOLISM; MIDDLE AGED; NERVE CELL; NUCLEOTIDE REPEAT; PATHOLOGY; REFERENCE VALUE;

AGED; AGED, 80 AND OVER; CAUDATE NUCLEUS; CELL SURVIVAL; CORPUS STRIATUM; FEMALE; HETEROZYGOTE; HUMANS; HUNTINGTON DISEASE; INTERNEURONS; MALE; MIDDLE AGED; NEURONS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; REFERENCE VALUES; REPETITIVE SEQUENCES, NUCLEIC ACID; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 0030612119     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410420213     Document Type: Article

References (41)

1. Hedreen JC, Folstein SE. Early loss of neostriatal striosome neurons in Huntington's disease. J Neuropathol Exp Neurol 1995;54:105-120
2. Morton AJ, Nicholson LFB, Faull RLM. Compartmental loss of NADPH diaphorase in the neuropil of the human striatum in Huntington's disease. Neuroscience 1993;53:59-168
3. Augood SJ, Faull RLM, Love DR, Emson PC. Reduction in enkephalin and substance P mRNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridisation study. Neuroscience 1996;72:1023-1036
4. Bird ED, Iversen LL. Huntington's chorea - post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in the basal ganglia. Brain 1974;97:457-472
5. Spokes EGS. Dopamine in Huntington's disease: a study of post-mortem brain tissue. In: Chase TN, Wexler NS, Barbeau A, eds. Advances in neurology, vol 23. New York: Raven Press, 1979:481-493
6. Chase TN. Biochemical and pharmacologic studies of monoamines in Huntington's chorea. In: Barbeau A, Chase TN, Paulson GW, eds. Advances in neurology, vol 1. New York: Raven Press, 1973:533-542
7. Antonini A, Schmid W, Spiegel R, Leenders KL. Cerebral glucose metabolism and striatal receptor density measured with PET in subjects at risk for Huntington's disease. Mov Disord 1992;7(suppl 1):145 (Abstract)
8. Leenders KL, Frackowiak RSJ, Quinn N, Marsden CD. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography. Mov Disord 1986;1:69-77
9. Sedvall G, Karlsson P, Lundin A, et al. Dopamine D1 receptor number - a sensitive PET marker for early brain degeneration in Huntington's disease. Eur Arch Psychiatry Clin Neurosci 1994;243:249-255
10. Turjanski N, Weeks R, Dolan R, et al. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain 1995;118:689-696
11. Klawans HL, Weiner WJ. The effect of d-amphetamine on choreiform movement disorders. Neurology 1974;24:312-318
12. Reveley MA, Dursun SM, Andrews H. A comparative trial use of sulpiride and risperidone in Huntington's disease: a pilot study. J Psychopharmacol 1996;10:162-165
13. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-1432
14. Norris PJ, Waldvogel HJ, Faull RLM, et al. Decreased neuronal nitric oxide synrhase messenger RNA and somatostatin messenger RNA in the striatum of Huntington's disease. Neuroscience 1996;72:1037-1047
15. Vonsattel J-P, Myers RH, Stevens TJ, et al. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44:559-577
16. Harrington KA, Augood SJ, Faull RLM, et al. Dopamine D1 receptor, D2 receptor, proenkephalin A and substance P gene expression in the caudate nucleus of control and schizophrenic tissue: a quantitative cellular in situ hybridisation study. Mol Brain Res 1995;33:333-342
17. Richfield EK, O'Brien CF, Eskin T, Shoulson I. Heterogeneous dopamine receptor changes in early and late Huntington's disease. Neurosci Lett 1991;132:21-26
18. Dawbarn D, De Quidt ME, Emson PC. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res 1985;340:251-260
19. Ferrante RJ, Beal MF, Kowall NW, et al. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res 1987;411:162-166
20. Ferrante RJ, Kowall NW, Beal MF, et al. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J Neuropathol Exp Neurol 1987; 46:12-27
21. Kawaguchi Y, Wilson CJ, Augood SJ, Emson PC. Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci 1995;18:527-535
22. Le Moine C, Tison F, Bloch B. D2 dopamine receptor gene expression by cholinergic neurons in the rat striatum. Neurosci Lett 1990;117:248-252
23. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72: 971-983
24. DiFiglia M, Sapp E, Chase K, et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995;14:1075-1081
25. Hoogeveen AT, Willemsen R, Meyer N, et al. Characterization and localization of the Huntington disease gene product. Hum Mol Genet 1993;2:2069-2073
26. Sharp AH, Loev SJ, Schilling G, et al. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 1995;14:1065-1074
27. Trottier Y, Devy D, Imbert G, et al. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet 1995;10:104-110
28. Li X-J, Li S-H, Sharp AH, et al. A huntingtin-associated protein enriched in brain with implications for pathology. Nature 1995;378:398-402
29. Gu M, Gash MT, Mann VM, et al. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 1996;39: 385-389
30. Beal MF. Neurochemistry and toxin models in Huntington's disease. Curr Opin Neurol 1994;7:542-547
31. Coyle JT, Puttfarcken P. Oxidative stress, glutamate and neu-rodegenerative disorders. Science 1993;262:689-695
32. DiFiglia M. Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci 1990;13:286-289
33. Beal MF, Brouillet E, Jenkins BG, et al. Neurochemical and histological characterisation of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993;13:4181-4192
34. Beal MF, Kowall NW, Ellison DW, et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986;321:168-171
35. Mallard EC, Waldvogel HJ, Williams CE, et al. Repeated asphyxia causes loss of striatal projection neurons in the fetal sheep brain. Neuroscience 1995;65:827-836
36. Nasir J, Floresco SB, O'Kusky JR, et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995;81:811-823
37. Augood SJ, McGowan EM, Emson PC. Expression of NMDA receptor subunit NR1 mRNA by identified striatal somatostatin cells. Neuroscience 1994;59:7-12
38. Medina L, Figueredo-Cardenas G, Reiner A. Differential abundance of Superoxide dismutase in interneurons versus projection neurons and in matrix versus striosome in monkey striatum. Brain Res 1996;708:59-70
39. Li X-J, Sharp AH, Li S-H, et al. Huntingtin-associated protein (HAP1): discrete neutonal localizations in the brain resemble those of neuronal nitric oxide synthase. Proc Nad Acad Sci USA 1996;93:4839-4844
40. Weeks RA, Harding AE, Brooks DJ. PET demonstrates a parallel loss of D1 and D2 dopamine receptors in asymptomatic gene carriers of Huntington's disease. Neurology 1995;45:A220
41. Weeks RA, Piccini P, Harding AE, Brooks DJ. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol 1996;40:49-54